Literature DB >> 16271942

Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation.

Bas A Schoonderwoerd1, Isabelle C Van Gelder, Dirk J Van Veldhuisen, Maarten P Van den Berg, Harry J G M Crijns.   

Abstract

Atrial fibrillation (AF) and congestive heart failure (CHF) are 2 frequently encountered conditions in clinical practice. Both lead to changes in atrial function and structure, an array of processes known as atrial remodeling. This review provides an overview of ionic, electrical, contractile, neurohumoral, and structural atrial changes responsible for initiation and maintenance of AF. In the last decade, many studies have evaluated atrial remodeling due to AF or CHF. Both conditions often coexist, which makes it difficult to distinguish the contribution of each. Because of atrial stretch in the setting of hypertension or CHF, atrial remodeling frequently occurs long before AF arises. Alternatively, AF may lead to electrical remodeling, that is, shortening of refractoriness due to the high atrial rate itself. In many experimental AF or rapid atrial pacing studies, the ventricular rate was uncontrolled. In those studies, atrial stretch due to CHF may have interfered with the high atrial rate to produce a mixed type of electrical and structural remodeling. Other studies have dissected the individual role of AF or atrial tachycardia from the role CHF plays in atrial remodeling. Atrial fibrillation itself does not lead to structural remodeling, whereas this is frequently produced by hypertension or CHF, even in the absence of AF. Primary and secondary prevention programs should tailor treatment to the various types of remodeling.

Entities:  

Mesh:

Year:  2005        PMID: 16271942     DOI: 10.1016/j.pcad.2005.06.014

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  22 in total

Review 1.  Scar homogenization in AF ablation: Evolution and practice.

Authors:  Minglong Chen
Journal:  J Atr Fibrillation       Date:  2017-06-30

Review 2.  Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?

Authors:  James A Reiffel
Journal:  J Atr Fibrillation       Date:  2008-05-16

Review 3.  Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications.

Authors:  Bandar Al Ghamdi; Walid Hassan
Journal:  J Atr Fibrillation       Date:  2009-06-01

4.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.

Authors:  J Zhao; J Li; W Li; Y Li; H Shan; Y Gong; B Yang
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

5.  Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG.

Authors:  B F McBride; T Yang; D M Roden
Journal:  Pharmacogenomics J       Date:  2009-02-10       Impact factor: 3.550

6.  Sinus bradycardia and sinus pauses immediately after electrical cardioversion of persistent atrial fibrillation--what do they mean?

Authors:  Dritan Poçi; Britt-Marie Abrahamsson; Nils Edvardsson; Lennart Bergfeldt
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-01-20       Impact factor: 1.468

7.  Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin.

Authors:  Fang Liu; Mark D Levin; Nataliya B Petrenko; Min Min Lu; Tao Wang; Li Jun Yuan; Andrea L Stout; Jonathan A Epstein; Vickas V Patel
Journal:  J Mol Cell Cardiol       Date:  2008-09-16       Impact factor: 5.000

Review 8.  Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure.

Authors:  George Karayannis; George Kitsios; Haralambos Kotidis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2007-04-21       Impact factor: 4.214

9.  New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future.

Authors:  Kapil Kumar; Peter J Zimetbaum
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10

Review 10.  Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Authors:  Gerald V Naccarelli; Frank Peacock
Journal:  Vasc Health Risk Manag       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.